Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PMS nanoparticles improve damaged hair by protecting and restoring its surface and color.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

This study observed that adherence to finasteride treatment in patients with benign prostatic hyperplasia at a clinic in Tepic Nayarit had not been previously evaluated in Mexico.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

This review discusses recent advances in polydopamine-based biomaterials and their growing potential in personalized medicine, but reports no new experimental results; the authors highlight both opportunities and challenges for future applications.

In this study, microneedle-assisted delivery of polyglutamate significantly improved hair parameters, scalp symptoms, and quality of life in androgenetic alopecia patients, with no serious adverse reactions reported.

This study found that methotrexate, when administered according to current recommendations, effectively manages rheumatoid arthritis for many patients in Poland, although regular monitoring is necessary due to possible adverse effects.

This study found that trametinib and vemurafenib increased sebum production and gene expression related to lipid accumulation in hamster sebocytes, which may help explain certain side effects in patients.

This study found that microneedle delivery of Polygonum multiflorum extract led to earlier pigmentation and hair regrowth in mice with androgenetic alopecia.

This study found that women with PCOS had significantly higher levels of the pro-inflammatory chemokine MIP-1α compared to controls, suggesting an association with low-grade chronic inflammation, though the increase in MIP-1β levels did not reach statistical significance.

This report details a case study where a 40-year-old woman experienced allergic contact dermatitis and angioedema-like symptoms after using PPD-containing hair dye. Patch testing confirmed a positive reaction to PPD, highlighting the substance's potential to cause both T-cell and IgE-mediated hypersensitivity reactions.

This article describes the Australian Medicines Handbook as a compact, readable, and comprehensive drug reference guide for Australian practitioners, but it does not present new research findings.

This study found that permanent makeup pigments were applied at similar depths as traditional tattoo inks in mice but faded over time due to larger inorganic pigments.

The digital system for measuring melasma shows promise but needs more development for better accuracy and automation.

This study found that PRP injections are safe and may slightly reduce penile curvature and improve PDQ scores in men with stable-phase Peyronie's Disease, but the changes are not significant enough to predict long-term effects.

This study found that the combination of MT-DADMe-ImmA and MTA selectively induced apoptosis in head and neck squamous cell carcinoma cell lines FaDu and Cal27, but not in normal fibroblasts or MTAP-deficient breast cancer cells.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This study reports that Mohs micrographic surgery resulted in no recurrences of pilomatrix carcinoma, compared to a 34.5% recurrence rate with traditional surgical excision.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

This case report examines a patient with myasthenia gravis, invasive thymoma, and paraneoplastic pemphigus associated with alopecia areata, notably without the usual mucosal involvement.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

This study found that PBMCsec has anti-fibrotic effects on mouse and human skin scars by regulating pro-fibrotic gene expression and inhibiting myofibroblast differentiation and elastic fiber breakdown.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

This study found that paclitaxel poliglumex induces significantly less and milder alopecia compared with standard taxanes in ovarian and breast cancer patients.